Drug Profile
Research programme: SIRT1 protein activators - Elixir
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Elixir Pharmaceuticals
- Class Small molecules
- Mechanism of Action SIRT1 protein stimulants; SIRT3 protein activators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity; Type 2 diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Obesity in USA (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in USA (PO)
- 01 Jul 2008 Elixir Pharmaceuticals and Boston University enter into an exclusive sirtuin intellectual property license agreement